A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer

Trial Profile

A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs FF 21101 Y-90 (Primary)
  • Indications Carcinoma; Colorectal cancer; Liposarcoma; Neuroendocrine tumours; Ovarian cancer; Soft tissue sarcoma; Solid tumours; Vulvovaginal cancer
  • Focus Adverse reactions
  • Sponsors FujiFilm Pharmaceuticals USA; Strategia Therapeutics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 05 Apr 2017 Results (n=7) assessing biodistribution, safety and therapeutic outcomes, presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 14 Jan 2016 Planned end date changed from 1 Jun 2018 to 1 Dec 2018, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top